Liu Ying, Luo Dan, Lu Yuangang, Tan Liuchang
Plastic surgery Department, Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing 100038, China.
Department of Dermatology, Daping Hospital, Army Medical University, Chongqing 400042, China.
Pathol Res Pract. 2025 May;269:155875. doi: 10.1016/j.prp.2025.155875. Epub 2025 Feb 27.
Cutaneous melanoma (SKCM) is a highly aggressive malignancy with an overall poor prognosis. The expression of E2F transcription factor 1 in SKCM tissues was analyzed using the data acquired from the Cancer Genome Atlas (TCGA)and Gene Expression Omnibus (GEO)databases. The expression of E2F1 was also analyzed in human biopsies using immunohistology, and its expression was detected in SKCM cell lines using qPCR and WB technology. The prognostic value of E2F transcription factor 1 in SKCM was investigated using Kaplan-Meier survival and Cox analysis. The Tumor Immunization Estimation Resource (TIMER) was used to analyze the invasion of immune cells and associated markers of immune cells. The prognostic value of E2F transcription factor 1 DNA methylation levels for each CpG was analyzed by means of the MethSurv. The results were verified in the Human Protein Atlas (HPA) database. Individuals with elevated E2F transcription factor 1 expression had a worse prognosis (HR=1.43, p = 0.01). Using the expression level of E2F transcription factor 1, a reliable distinction between tumor and normal tissues can be made (Area Under the Curve =0.949). Moreover, immune infiltrations analysis showed that the mRNA expression levels and somatic copy number alterations (SCNA) in E2F transcription factor 1 were significantly correlated with recruitment of several immune cells. Our study showed that overexpression of E2F transcription factor 1 was significantly associated with poor prognosis and malignant phenotype of melanoma cells in SKCM patients.
皮肤黑色素瘤（SKCM）是一种侵袭性很强的恶性肿瘤，总体预后较差。利用从癌症基因组图谱（TCGA）和基因表达综合数据库（GEO）获取的数据，分析了E2F转录因子1在SKCM组织中的表达情况。还通过免疫组织化学分析了人体活检组织中E2F1的表达，并使用qPCR和WB技术在SKCM细胞系中检测其表达。采用Kaplan-Meier生存分析和Cox分析研究了E2F转录因子1在SKCM中的预后价值。利用肿瘤免疫评估资源（TIMER）分析免疫细胞的浸润情况以及免疫细胞的相关标志物。通过MethSurv分析每个CpG的E2F转录因子1 DNA甲基化水平的预后价值。结果在人类蛋白质图谱（HPA）数据库中得到验证。E2F转录因子1表达升高的个体预后较差（HR=1.43，p = 0.01）。利用E2F转录因子1的表达水平，可以可靠地区分肿瘤组织和正常组织（曲线下面积=0.949）。此外，免疫浸润分析表明，E2F转录因子1中的mRNA表达水平和体细胞拷贝数改变（SCNA）与几种免疫细胞的募集显著相关。我们的研究表明，E2F转录因子1的过表达与SKCM患者黑色素瘤细胞的不良预后和恶性表型显著相关。
